That was my point, those 2 and a bunch of others as well.
In message #msg-146260318 you said,
All told, the above is (IMO) a well-conceived plan to support multiple aesthetic and therapeutic indications without incurring unduly high clinical-trial expenses.
So do you believe the company can continue to burn 160 million yearly PLUS the added expenses of a go it alone strategy related to cosmetic launch in US and still be a good investment in the next 2-3 years for existing shareholders? Doesn't something have to give here? Or is your horizon long enough such that the 2-3 time frame is not major concern. If so, I am sure in the wrong investment. I am here to make money, preferably before I am 6 feet under
FEATURED ECGI Signs Definitive $25 Million Agreement to Acquire RezyFi • Mar 24, 2026 8:30 AM
Cannabix Technologies Announces First Delivery of Marijuana Breath Test (MBT) to a Major Construction Client • BLOZF • Mar 19, 2026 12:45 PM
ECGI Building in Crypto's Top-Performing Sector as Tokenized Real-World Assets Surge Past $26 Billion • ECGI • Mar 19, 2026 8:30 AM
Advances in Domestic Heavy Rare Earth Minerals Production Essential for North American Defense Stockpiles • ALOY • Mar 18, 2026 9:00 AM
ECGI Advances $10M Mortgage Tokenization Pilot as SEC Interpretation Adds Clarity • ECGI • Mar 18, 2026 8:45 AM
ECGI Advances Mortgage Tokenization Pilot as Institutional Market Rails Continue to Develop • ECGI • Mar 17, 2026 8:30 AM
